A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

NCT04502446 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Patients to be followed up in the CRSP-ONC-LTF study

Conditions

T Cell Lymphoma

Interventions

BIOLOGICAL: CTX130

Sponsor

CRISPR Therapeutics AG